Sanara MedTech (NASDAQ: SMTI) furnishes 2026 outlook deck

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Sanara MedTech Inc. filed a current report to furnish an investor presentation it plans to use with investors and analysts, including at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026. The presentation, attached as Exhibit 99.1, outlines the company’s priorities, strategy and anticipated revenue for fiscal 2026.

The company notes this information is being furnished under Regulation FD, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other Securities Act or Exchange Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/02/2026 - 04:11 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2026

SANARA MEDTECH INC.

(Exact name of registrant as specified in its charter)

Texas	001-39678	59-2219994
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation)		Identification No.)

1200 Summit Avenue, Suite 414

Fort Worth, Texas

76102

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (817) 529-2300

(Former name or former address, if changed since last report)

Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

SMTI

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure.

Sanara MedTech Inc. (the “Company”) is furnishing a copy of an investor presentation (the “Presentation”) that the Company intends to use, in whole or in part, in one or more meetings with investors or analysts, including during the Company’s presentation at the TD Cowen 46th Annual Health Care Conference to be held in Boston, Massachusetts on March 3, 2026. A copy of the Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The Presentation contains, among other things, a summary of the Company’s priorities, strategy and anticipated revenue for the 2026 fiscal year. The information contained in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Presentation, although it may do so from time to time as its management believes is warranted.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section. Further, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation language in such filing. Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Investor Presentation (furnished pursuant to Item 7.01).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:	March 2, 2026

		Sanara MedTech Inc.

		By:	/s/ Elizabeth B. Taylor
		Name:	Elizabeth B. Taylor
		Title:	Chief Financial Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Sanara MedTech Inc. (SMTI) disclose in this 8-K filing?

Sanara MedTech Inc. furnished an investor presentation as Exhibit 99.1. The presentation summarizes the company’s priorities, strategy and anticipated revenue for fiscal 2026 and will be used in meetings with investors and analysts, including at a TD Cowen health care conference.

How will Sanara MedTech (SMTI) use the investor presentation?

Sanara MedTech plans to use the investor presentation in meetings with investors and analysts. It specifically mentions use during the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026, to communicate its priorities, strategy and anticipated 2026 revenue.

Is Sanara MedTech’s investor presentation considered filed with the SEC?

No, the investor presentation is being furnished, not filed. The company states the information in Item 7.01 and Exhibit 99.1 is not deemed filed for Exchange Act Section 18 purposes and is not automatically incorporated by reference into Securities Act or Exchange Act filings.

What topics are covered in Sanara MedTech’s 2026 investor presentation?

The investor presentation includes a summary of Sanara MedTech’s priorities, overall strategy and anticipated revenue for the 2026 fiscal year. It is intended to be read together with the company’s other SEC filings and public announcements for fuller context on its business outlook.

Does Sanara MedTech (SMTI) commit to updating the investor presentation?

Sanara MedTech states it has no duty or obligation to publicly update or revise the investor presentation. Management may choose to update it from time to time if they believe updates are warranted, but there is no ongoing commitment described.

What exhibits are included with Sanara MedTech’s March 2, 2026 8-K?

The 8-K includes two exhibits: Exhibit 99.1, which is the investor presentation furnished under Item 7.01, and Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document accompanying the report.

Filing Exhibits & Attachments

26 documents